Heart disease is a leading cause of morbidity and mortality worldwide. Myocardial 
Introduction
Heart failure, especially myocardial infarction (MI) , is one of the main causes of morbidity and mortality in the world [1] .
MI results in the loss of irreplaceable contractile elements. The necrotic tissue is removed by macrophages and replaced with granulation tissue, resulting in a collagenous scar. During this process, the infarcted wall thins, the left ventricular (LV) chamber dilates, and interstitial fibrosis and cardiomyocyte hypertrophy appear in the non-infarcted region of the ventricle. These changes are linked
with the cardiac dysfunction that leads to heart failure [2] . [3] . Therefore, it is desirable to develop alternative strategies to repair hearts with infarction to ameliorate both patient prognosis and life quality.
Heart transplantation is a therapeutic option but limited by the insufficiency of donor organs. In addition, lifelong immune suppression often causes serious complications
For nearly a decade, researchers have investigated the possibility of cell transplantation for cardiac repairs [4] . Multiple cell types have been considered for such therapies, including skeletal myoblasts [5] , bone marrow-derived haematopoietic stem cells [6] , mesenchymal stem cells [7] , intrinsic cardiac stem cells (CSCs) [8] , embryonic stem cells (ESCs) [9] [10] [11] and induced pluripotent stem (iPS) cells [12] . Although studies have shown that cardiac performance by cell-based therapy has improved, unsatisfactory cell retention and transplant survival still plague this technique [13] [14] [15] . It is reported that, when delivered to the heart through a needle, approximately 90% of cells were lost to the circulation or leaked out of the injection site [13] . In the cells that successfully entered the heart, almost 90% died within the first week [14, 15] . Cell death was reported to be initiated by three principal pathways: ischaemia, anoikis and inflammation-related factors [16] .
The emerging field of tissue engineering may offer promising alternatives. Tissue Engineering, according to Langer and Vacanti, is ' an interdisciplinary field that applies the principles of engineering and life sciences towards the development of biological substitutes that restore, maintain or improve tissue functions' [17] . [18] . With the rapid development in tissue engineering, various tissues, such as cartilage [19] , bone [20] , skin [21] , nerve [22] , liver [23] , uterus [24] , blood vessel [25] and cardiac muscle, have been reconstructed [26, 27] . Platforms for tissue engineering are also employed in cancer research [28] .
The aim of tissue engineering is to repair or replace damaged organs and/or tissues by delivering functional cells, supporting scaffolds, growth-promoting molecules or genes and electric or physiologic signals to organs in need
The ultimate goal in cardiac tissue engineering is to generate biocompatible, non-immunogenic heart muscles with morphological and functional properties of natural myocardium [3] . For this purpose, about four distinguishable tissue engineering modalities have been established over the last decade. They include: (1) the cell sheet approach -a technique to detach and serially stack monolayer cell cultures to form contractile heart tissue sandwiches [29] ; (2) the decellularization-recellularization approach -a way to strip tissues of all cellular components while retaining their extracellular matrix structure as a reseeding substrate for heart or cardiogenic stem cells [30] ; (3) [12] .
Despite the progress of reprogramming somatic cells into iPS cells, iPS cells applied in tissue engineering research are still at preliminary stage. In view of the similarity of iPS cells with ESC, the problems that puzzle the ESC researchers also confront the iPS researchers. Even though some reports on iPS cell differentiation into cardiac tissue existed, research on iPS cells to treat MI is insufficient. So far there has been no report on delivering iPS cells in injectable scaffolds to improve cardiac function. However, because the research on iPS involves no ethical and social disputes, the injected myocardial tissue engineering using iPS cells as a seeding cell holds a great potential in the future therapeutic applications.

Adult stem cells
The potential for using ESCs to treat MI is confirmed by independent groups [16, 40] [79, 80] . However, a latest report that compared effect of adiposederived stem cell (ASC) and MSC in the infarcted heart revealed that acute donor cell death upon transplantation was their common barrier in improving cardiac function [81] . [108] . Angiogenesis induced by chitosan in an infarcted heart was found in our study for the first time. The mechanism needs further investigation. 
Other adult stem cells
Besides the widely studied stem cell sources described above, many other adult stem cell sources have been studied as candidates for myocardial repairs, including adipose-derived stem cells, peripheral blood-derived stem cells, cord blood-derived stem cells and endothelial progenitor cells, etc. [75-77]. Among them, adipose tissue is the only one that allows extraction in a large volume with minimal invasion. Adiposederived stem cells were initially isolated and characterized by Zuk et al. in 2001 [78]. Ease of isolation, availability in large number and multi-differentiation potential make them particularly appealing in regenerative medicine. Now these cells have been confirmed definitely to be similar to bMSC and their potential of cardiac repairs has also been determined by independent groups
Biomaterials in the injectable cardiac tissue engineering
The biomaterials play key roles in tissue engineering. In addition to the basic requirements (biocompatible, biodegradable, and biomimetic), the biomaterials in injectable cardiac tissue engineering must be injectable and capable of gel in situ after injection in order to support the LV wall, avoid the post-MI negative remodelling or deliver cells directly into the infarcted wall to
Other biomaterials
